Our understanding of feline chronic kidney disease (CKD) is advancing, and we now have more tools than ever before for diagnosing and monitoring this condition in the early stages.
The mainstay of management for feline CKD is dietary intervention, which has been shown to slow disease progression and increase survival time.
Nutritional modifications include moderate amounts of high-quality protein, phosphorus restriction, and omega 3 fatty acid supplementation, among others. However, identifying when to start feeding a renal diet is not always straightforward due to the insensitivity of serum phosphate concentrations for assessing CKD-mineral and bone disturbances (CKD-MBD). Now we have the ability to measure fibroblast growth factor-23 (FGF-23), a sensitive marker of early CKD-MBD, which allows us to detect cats in need of dietary phosphate restriction earlier and more accurately. Moreover, we have more commercial CKD diets available that allow us to customize the dietary management to the stage of disease.
The key learning objectives for this webinar are:
To review how we can diagnose cats in IRIS stage 1 and 2 CKD
To review what CKD-MBD is and understand the role of FGF-23 in this condition
To understand when and how to measure serum FGF-23 concentrations in cats with CKD
To review existing evidence regarding when to initiate dietary management in feline CKD
To assess commercial feline CKD diets to choose the best option to each patient, according to stage of disease and nutritional assessment.